RU2691105C1 - Лекарственные соединения - Google Patents

Лекарственные соединения Download PDF

Info

Publication number
RU2691105C1
RU2691105C1 RU2016123363A RU2016123363A RU2691105C1 RU 2691105 C1 RU2691105 C1 RU 2691105C1 RU 2016123363 A RU2016123363 A RU 2016123363A RU 2016123363 A RU2016123363 A RU 2016123363A RU 2691105 C1 RU2691105 C1 RU 2691105C1
Authority
RU
Russia
Prior art keywords
methyl
amino
dihydropyrimido
phenyl
dichlorophenyl
Prior art date
Application number
RU2016123363A
Other languages
English (en)
Russian (ru)
Other versions
RU2016123363A (ru
Inventor
Тимоти Харрисон
Грэхем ТРЕВИТТ
Питер Робин ХЬЮИТТ
Колин Родерик О'ДОУД
Франк Буркамп
Эндрю Джон УИЛКИНСОН
Стивен Д. ШЕФЕРД
Юг МИЭЛЬ
Original Assignee
Олмак Дискавери Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олмак Дискавери Лимитед filed Critical Олмак Дискавери Лимитед
Publication of RU2016123363A publication Critical patent/RU2016123363A/ru
Application granted granted Critical
Publication of RU2691105C1 publication Critical patent/RU2691105C1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016123363A 2013-12-19 2014-12-19 Лекарственные соединения RU2691105C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322602.2 2013-12-19
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
RU2016123363A RU2016123363A (ru) 2018-01-25
RU2691105C1 true RU2691105C1 (ru) 2019-06-11

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016123363A RU2691105C1 (ru) 2013-12-19 2014-12-19 Лекарственные соединения

Country Status (28)

Country Link
US (1) US9850247B2 (https=)
EP (1) EP3083625B1 (https=)
JP (1) JP6437559B2 (https=)
KR (1) KR102405462B1 (https=)
CN (1) CN105829315B (https=)
AU (1) AU2014369457B2 (https=)
BR (1) BR112016014151B1 (https=)
CA (1) CA2933755C (https=)
CY (1) CY1120035T1 (https=)
DK (1) DK3083625T3 (https=)
ES (1) ES2650013T3 (https=)
GB (1) GB201322602D0 (https=)
HR (1) HRP20180080T1 (https=)
HU (1) HUE037908T2 (https=)
IL (1) IL245672B (https=)
LT (1) LT3083625T (https=)
MX (1) MX371108B (https=)
NO (1) NO3083625T3 (https=)
NZ (1) NZ720178A (https=)
PL (1) PL3083625T3 (https=)
PT (1) PT3083625T (https=)
RS (1) RS56731B1 (https=)
RU (1) RU2691105C1 (https=)
SG (1) SG11201603814TA (https=)
SI (1) SI3083625T1 (https=)
SM (1) SMT201800020T1 (https=)
WO (1) WO2015092431A1 (https=)
ZA (1) ZA201603337B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137593B (zh) * 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト Wee1キナーゼ阻害剤、並びにそれを作製及び使用する方法
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmpシグナル阻害化合物
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
CN110678169A (zh) 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
CN110914277B (zh) * 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
SG11202003974XA (en) 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
US12220415B2 (en) 2018-02-28 2025-02-11 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
KR102697799B1 (ko) 2019-03-22 2024-08-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
WO2020210377A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
SI3964510T1 (sl) 2019-04-30 2024-10-30 Wuxi Biocity Biopharmaceutics Co., Ltd. Kristalna oblika WEE1 inhibitorske spojine in njena uporaba
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
EP4221710A4 (en) * 2020-10-01 2024-09-18 University of Washington DRUG-LIKE MOLECULES AND METHODS FOR THERAPEUTIC TARGETING OF MICRORNA-21
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
CN116601153B (zh) * 2020-12-18 2025-10-28 葛兰素史密斯克莱知识产权发展有限公司 作为nav1.8抑制剂的含氮2,3-二氢喹唑啉酮化合物
EP4262978A1 (en) * 2020-12-18 2023-10-25 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases
KR20240004539A (ko) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
BR112023025403A2 (pt) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制pkmyt1之化合物治療癌症之方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
EA023796B1 (ru) * 2010-12-06 2016-07-29 Глэксо Груп Лимитед ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR100881050B1 (ko) 2004-03-15 2009-01-30 에프. 호프만-라 로슈 아게 신규 디클로로―페닐―피리도 [2,3-d] 피리미딘 유도체, 그들의 제조 및 약제로서의 용도
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
JP5129812B2 (ja) 2007-06-15 2013-01-30 Msd株式会社 ビシクロアニリン誘導体
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
AU2009325400A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
AU2009325398A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2013012681A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023796B1 (ru) * 2010-12-06 2016-07-29 Глэксо Груп Лимитед ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Xu,Tianfeng et al., Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine 790 to Methionine 790 (T790M) Mutants. Angewandte Chemie, International Edition, 2013, 52(32), 8387-8390 (English) *
Xu,Tianfeng et al., Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine 790 to Methionine 790 (T790M) Mutants. Angewandte Chemie, International Edition, 2013, 52(32), 8387-8390 (English) (реферат, найдено DATABASE CASREACT (Online), Retrieved from STN, AN 159:339869, соединения с RN 1449423-84-0P, RN 1449423-85-1P, RN 1449423-86-2P, RN 1449423-87-3P, RN 1449423-88-4P, RN 1449423-89-5P, RN 1449423-90-8P, RN 1449423-91-9P. Martin, Mathew W. et al., Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity. Journal of Medicinal Chemistry, 2008, 51(6), 1637-1648 (English). Liew, Chin Y. et al., SVM Model for Virtual Screening of Lck Inhibitors. Journal of Chemical Information and Modeling, (English), 2009, 49 (4), 877-885 (реферат, найдено DATABASE CASREACT (Online), Retrieved *

Also Published As

Publication number Publication date
EP3083625A1 (en) 2016-10-26
HUE037908T2 (hu) 2018-09-28
CN105829315A (zh) 2016-08-03
SMT201800020T1 (it) 2018-05-02
CY1120035T1 (el) 2018-12-12
NZ720178A (en) 2022-05-27
CA2933755A1 (en) 2015-06-25
KR20160098499A (ko) 2016-08-18
AU2014369457B2 (en) 2018-08-09
PT3083625T (pt) 2018-02-06
US20160318936A1 (en) 2016-11-03
EP3083625B1 (en) 2017-11-01
RS56731B1 (sr) 2018-03-30
DK3083625T3 (en) 2017-12-18
KR102405462B1 (ko) 2022-06-03
ZA201603337B (en) 2018-07-25
NO3083625T3 (https=) 2018-03-31
BR112016014151B1 (pt) 2023-01-17
MX371108B (es) 2020-01-17
IL245672A0 (en) 2016-06-30
CN105829315B (zh) 2019-03-08
LT3083625T (lt) 2017-12-27
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
GB201322602D0 (en) 2014-02-05
US9850247B2 (en) 2017-12-26
JP6437559B2 (ja) 2018-12-12
BR112016014151A2 (https=) 2017-08-08
IL245672B (en) 2021-10-31
HRP20180080T1 (hr) 2018-03-09
SG11201603814TA (en) 2016-07-28
CA2933755C (en) 2023-01-31
AU2014369457A1 (en) 2016-06-09
JP2017500335A (ja) 2017-01-05
RU2016123363A (ru) 2018-01-25
ES2650013T3 (es) 2018-01-16
WO2015092431A1 (en) 2015-06-25
PL3083625T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
RU2691105C1 (ru) Лекарственные соединения
US10766903B2 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
US10766902B2 (en) Wee-1 inhibiting pyrazolopyrimidinone compounds
JP6412920B2 (ja) 2−アミノピリド[4,3−D]ピリミジン−5−オン誘導体及びWee−1阻害薬としてのそれらの使用
AU2019205984A1 (en) 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo [3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
WO2018011570A1 (en) Wee-1 inhibiting pyridopyrimidinone compounds
EP3110819A1 (en) Heterocyclic compounds
EP3746432B1 (en) 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19)
US20240327382A1 (en) Pharmaceutical compounds as inhibitors of ubiquitin specific protease 19
CN109836427B (zh) 嘧啶并嘧啶酮类化合物及其应用
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
HK1227877B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1227877A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors